Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

GlaxoSmithKline : Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 03:31pm CET

GlaxoSmithKline plc on November 8 announced that Dr Hal Barron has been appointed Chief Scientific Officer and President, R&D, GSK. He has also been appointed as an Executive Director to the GSK Board. Dr Barron will assume his new role and join the Board on 1 January 2018.

Dr Barron is currently President R&D at Calico (California Life Sciences LLC), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to joining Calico, Dr Barron was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President Development and Chief Medical Officer, according to GlaxoSmithKline.

Emma Walmsley, CEO, GSK said: Scientific innovation must be at the heart of GSK and with the appointment of Hal, we are bringing one of the worlds foremost R&D leaders to the company.

Hal has exceptional experience and a strong track record of developing significant new medicines from his time at Roche and Genentech; whilst at Calico he has helped build a research organisation that uses cutting-edge technologies in drug discovery and development. He is also very well known for his integrity, for being a clinician who is committed to always doing the best he can for patients and for building exceptional teams.

The fusion of science and technology is fast transforming pharmaceuticals R&D. With Hal, we have a new R&D leader who will drive the changes and choices we need to make to be successful in this new environment, and as we look to build the next wave of growth for the company.

Philip Hampton, Chairman, GSK, said: We are delighted that Hal will be joining GSK and look forward to welcoming him to the Board. He is a highly respected clinician-scientist with a proven ability to generate value for shareholders and his appointment reflects the Boards commitment to investing in research and development.

Dr Barron said, I am honoured to have been chosen for this important position especially given the companys renewed focus on discovering and developing transformational new medicines. GSK is a company with a rich history of innovation, with many talented scientists who care deeply about translating great science into therapies that make a meaningful difference for patients. I believe there is a significant opportunity to accelerate this effort and am looking forward to joining Emma and the team on this mission.

During his time at Genentech and Roche, Dr Barron oversaw the development of Xolair (Asthma), Avastin (multiple tumour types), Tarceva (Lung Cancer), Lucentis (AMD), Actemra (Rheumatology), Zelboraf and Erivedge (Melanoma), Perjeta and Kadcyla (Breast Cancer), as well as Gazyva (CLL). He has overseen pioneering work in oncology, personalised medicine and has led teams across the USA, Europe and Asia.

Prior to joining Genentech as a clinical scientist in 1996, Dr Barron received his Bachelor of Science in physics from Washington University in St. Louis, his medical degree from Yale University, and completed his training in Cardiology and Internal Medicine at the University of California San Francisco.

Dr Barrons academic positions include adjunct professor at the University of California, San Francisco. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.

Dr Barron will be based in the US, while operating from offices in both San Francisco and Stevenage in the UK. The new office presence in San Francisco will be focused on business development for R&D.

(c) 2017 Palestine News & Information Agency (WAFA). All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
02/16GLAXOSMITHKLINE : GSK submits landmark IMPACT data to European Medicines Agency ..
AQ
02/15GLAXOSMITHKLINE : Details Findings in Organic Research [High-Throughput Automate..
AQ
02/15GLAXOSMITHKLINE : An Application for the Trademark "ELEBRATO" Has Been Filed by ..
AQ
02/15FINDINGS FROM GLAXOSMITHKLINE PLC IN : Efficacy,...
AQ
02/15GLAXOSMITHKLINE : Reports from GlaxoSmithKline plc Provide New Insights into Bio..
AQ
02/15GLAXOSMITHKLINE : Investigators at GlaxoSmithKline plc Release New Data on Monoc..
AQ
02/15GLAXOSMITHKLINE : New Whooping Cough Study Results from GlaxoSmithKline plc Desc..
AQ
02/15GLAXOSMITHKLINE : GSK receives European approval for expanded indication for Flu..
PU
02/14GLOBAL EYE CANCER MARKET REPORT WITH : Global Eye Cancer Market - Global Industr..
AQ
02/14GLAXOSMITHKLINE : GSK submits landmark IMPACT data - Trelegy Ellipta
PU
More news
News from SeekingAlpha
02/16WALL STREET BREAKFAST : Major Recovery For Wall Street 
02/16'Intense' flu season to continue 
02/15YOUR DAILY PHARMA SCOOP : Achaogen Update, Catabasis' Positive Results, Bristol-.. 
02/15Expanded use for Glaxo's flu vaccine Fluarix Tetra OK'd in Europe 
02/15Lanny's January Dividend Income Summary 
Financials ( GBP)
Sales 2018 30 305 M
EBIT 2018 8 227 M
Net income 2018 4 129 M
Debt 2018 13 333 M
Yield 2018 6,07%
P/E ratio 2018 15,09
P/E ratio 2019 13,75
EV / Sales 2018 2,60x
EV / Sales 2019 2,52x
Capitalization 65 379 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 15,3  GBP
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-1.67%91 131
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572